Study analysis · Clinical Research in Cardiology · 2025
After a heart attack, only 27.5% of patients in GP care hit the cholesterol goal, versus 72.5% in a specialized lipid clinic.
Heart attack patients who stayed in a specialized cholesterol clinic were much more likely to keep their bad cholesterol low than those who switched to a regular doctor, but the study was small and not randomized.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study watched two groups of heart attack patients: one group got extra care at a special lipid clinic, and the other went to their regular doctor. It can show a link between the type of care and health outcomes, but because patients chose their group and were not randomly assigned, it cannot prove that one type of care caused the difference.
What’s the bottom line?
After a severe heart attack, patients got strong cholesterol drugs. One year later, some stayed in a special lipid clinic, while others went to their regular doctor. Two years later, the special clinic patients had much better cholesterol control.
How strong is this study?
The study followed 85 patients for two years and measured cholesterol and heart problems, which is useful. But it was small, from one hospital, and the two groups might have been different in other ways, so we should be careful trusting the results until bigger randomized studies confirm them.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
40 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=85)+6.9/20
- Follow-up+10/10
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 548 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is a non-randomized, single-center observational cohort study. Patients self-selected to continue in the outpatient lipid clinic or transition to GP care, so groups may differ in unmeasured ways (e.g., health literacy, socioeconomic status, disease severity, adherence). Confounding by indication, selection bias, and small sample size prevent causal inference. Associations between less intensive lipid-lowering therapy, higher LDL-C, and MACE cannot be interpreted as cause-effect relationships.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding sources were disclosed in the manuscript.
The provided text contains no conflict of interest section, no funding statement, and no author affiliations or disclosure statements. The study appears to be an academic, single-center investigation. However, the absence of explicit disclosure prevents full verification of potential conflicts.
Key takeaways
- 01
In the special clinic group, 72.5 out of 100 reached the cholesterol goal vs 27.5 out of 100 in the GP group.
- 02
Average LDL cholesterol was 1.2 vs 2.1 mmol/L.
- 03
Time spent at the cholesterol goal was 82.4% vs 62.4%.
- 04
Heart events occurred in 7.5% vs 18.8%.
- 05
For every 100 patients, about 45 more reached the cholesterol goal with the special clinic.
- 06
For heart events, about 8 in 100 in the special clinic had an event vs about 19 in 100 with GP care — an absolute difference of about 11 in 100 — but this difference was not statistically significant, so it could be due to chance.
- 07
The absolute risk reduction for heart events was not statistically significant in this small study.
Surprising findings
- Deprescribing of lipid-lowering therapy by GPs was a bigger cause of missed LDL-C targets than patient non-adherence.Many people assume patients not taking their pills is the main reason cholesterol goals are missed, but this study points to doctors stopping effective medications.
- All patients reached the recommended LDL-C target at 12 months, but by 24 months only 60% of the whole cohort remained at target.Early intensive treatment worked for everyone initially, yet durability was poor once follow-up changed.
- MACE was numerically much lower in the lipid clinic group (7.5% vs 18.8%) but was not statistically significant.The absolute difference is large—11.3 percentage points—but the small sample size means it could easily be due to chance.
- Patients who had a MACE during follow-up had spent significantly less time at LDL-C target and had higher LDL-C at 24 months.It reinforces the link between sustained cholesterol control and heart outcomes, even in a small observational study.
Practical takeaways
If you or a loved one has had a heart attack, ask about structured lipid clinic follow-up or ensure your GP is committed to aggressive LDL-C targets.
This was a small, non-randomized, single-center observational study; it cannot prove that lipid clinic care causes better outcomes.
medium confidenceIf a doctor wants to stop your lipid-lowering medication after a heart attack, ask why and whether it aligns with very-high-risk guidelines.
Deprescribing can sometimes be appropriate due to side effects or drug interactions; this study only highlights that it was the main cause of missed targets in this cohort.
medium confidenceTrack your LDL-C over time and aim for sustained time at target, not just a single good reading.
The study did not report confidence intervals or effect sizes, and the MACE analysis was underpowered.
medium confidenceIf you are a clinician or health system designer, consider whether guideline discrepancies between GPs and specialists are putting patients at risk.
The study is from one German center and may not generalize to other health systems.
low confidenceWhy this study matters
The 45-point cholesterol goal gap
At 24 months, 72.5% of patients followed in a specialized lipid clinic reached the LDL-C target of ≤1.4 mmol/L, compared with only 27.5% of those who switched to GP care. That is an absolute difference of 45 percentage points (p=0.037) in an 85-patient cohort.
It shows a huge, easily understandable difference in a key heart-health metric based simply on where follow-up happens.
Bad cholesterol nearly doubled in GP care
Mean LDL-C at 24 months was 1.2 ± 0.7 mmol/L in the lipid clinic group versus 2.1 ± 1.04 mmol/L in the GP group (p<0.01). That is an absolute difference of about 0.9 mmol/L.
A near-doubling of bad cholesterol after a heart attack could translate into meaningful long-term risk differences.
Time on target: consistency matters
Patients in the lipid clinic spent 82.4 ± 29.5% of time at LDL-C target, compared with 62.4 ± 36.6% in the GP group (p<0.01). That is an absolute difference of about 20 percentage points in time spent at goal.
It is not just one cholesterol reading—it is how long you stay protected over two years.
MACE: a tantalizing but uncertain signal
MACE occurred in 7.5% of the lipid clinic group versus 18.8% of the GP group—an absolute difference of 11.3 percentage points—but this was not statistically significant in the small 85-patient study.
The heart-event difference is large enough to grab attention, but the study was underpowered, so it could be chance.
Deprescribing by GPs beat patient non-adherence as the main problem
The main cause of missed LDL-C targets was deprescribing of lipid-lowering therapy by local GPs, and those patients had higher mean LDL-C than those who simply did not adhere: 2.1 ± 1.04 mmol/L vs 1.52 ± 0.53 mmol/L (p<0.01).
It challenges the common assumption that patients are the main reason cholesterol targets are missed.
Guideline conflict: <55 mg/dL vs <70 mg/dL
The study highlights that cardiologists follow ESC/EAS guidelines targeting LDL-C <55 mg/dL for very high-risk patients, while many German GPs follow the Nationale Versorgungsleitlinie recommending a 'fire-and-forget' strategy with a less intensive <70 mg/dL target.
It suggests the problem may be systemic guideline confusion, not just individual doctor behavior.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
After a severe heart attack, patients got strong cholesterol drugs. One year later, some stayed in a special lipid clinic, while others went to their regular doctor. Two years later, the special clinic patients had much better cholesterol control.
Research results
In the special clinic group, 72.5 out of 100 reached the cholesterol goal vs 27.5 out of 100 in the GP group. Average LDL cholesterol was 1.2 vs 2.1 mmol/L. Time spent at the cholesterol goal was 82.4% vs 62.4%. Heart events occurred in 7.5% vs 18.8%.
What this means - more context
For every 100 patients, about 45 more reached the cholesterol goal with the special clinic. For heart events, about 8 in 100 in the special clinic had an event vs about 19 in 100 with GP care — an absolute difference of about 11 in 100 — but this difference was not statistically significant, so it could be due to chance. The absolute risk reduction for heart events was not statistically significant in this small study.
To evaluate whether continuing follow-up in a specialized outpatient lipid clinic versus transitioning to general practitioner (GP) care after STEMI affects LDL-C target attainment, time on target, and major adverse cardiac events (MACE) at 24 months in the 'Jena auf Ziel' cohort.
In this prospective single-center cohort of 85 STEMI patients, all received intensive lipid-lowering therapy and reached LDL-C <55 mg/dL by 12 months. From 12 to 24 months, 53 patients stayed in the outpatient lipid clinic and 32 switched to GP care. At 24 months, the lipid clinic group had significantly higher LDL-C target attainment (72.5% vs 27.5%; absolute difference 45 percentage points; p=0.037), lower mean LDL-C (1.2 vs 2.1 mmol/L; p<0.01), and longer time on target (82.4% vs 62.4%; p<0.01). MACE occurred in 7.5% vs 18.8% (absolute difference 11.3 percentage points), but this was not statistically significant. GP deprescribing of lipid-lowering therapy was the main cause of missed targets.
Methods Used
Prospective cohort study of 85 patients admitted with STEMI to Jena University Hospital in 2021. All started atorvastatin 80 mg plus ezetimibe, with escalation to bempedoic acid or PCSK9 inhibitors as needed. At 12 months, patients chose either continued outpatient lipid clinic follow-up (n=53) or GP standard care (n=32). At 24 months, researchers compared prescribed lipid-lowering drugs, LDL-C target attainment, LDL-C time on target, and MACE.
Main Finding
At 24 months, specialized lipid clinic follow-up vs GP care was associated with higher absolute LDL-C target attainment (72.5% vs 27.5%; absolute difference 45 percentage points; p=0.037), lower mean LDL-C (1.2 vs 2.1 mmol/L; p<0.01), and longer time on target (82.4% vs 62.4%; p<0.01). MACE occurred in 7.5% vs 18.8% (absolute difference 11.3 percentage points), but the difference was not statistically significant. Deprescribing by GPs was the main reason for missed LDL-C targets.
Confidence Level
Low to moderate. No retraction or corrections. Small single-center non-randomized cohort (n=85), treatment groups self-selected, no confidence intervals or effect sizes reported, and the MACE analysis was underpowered.
Study Flags
Red Flags
- •Small sample (n=85) and underpowered for MACE
- •Non-randomized treatment selection (patients chose clinic vs GP) and single-center design
- •No confidence intervals or effect sizes reported; retrospective limitation noted
Surprising Findings
Deprescribing of lipid-lowering therapy by GPs was a bigger cause of missed LDL-C targets than patient non-adherence.
Many people assume patients not taking their pills is the main reason cholesterol goals are missed, but this study points to doctors stopping effective medications.
Practical Takeaways
If you or a loved one has had a heart attack, ask about structured lipid clinic follow-up or ensure your GP is committed to aggressive LDL-C targets.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 548 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study watched two groups of heart attack patients: one group got extra care at a special lipid clinic, and the other went to their regular doctor. It can show a link between the type of care and health outcomes, but because patients chose their group and were not randomly assigned, it cannot prove that one type of care caused the difference.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Prospective follow-up of a defined STEMI cohort with complete 24-month follow-up of all 85 patients.
- Objective laboratory measurement of LDL-C and structured assessment of LDL-C target attainment.
- Clinically relevant outcome of MACE, although event numbers were small.
Weaknesses
- Non-randomized allocation: patients chose whether to continue specialized lipid clinic follow-up or transfer to GP care.
- Small sample size and low MACE event count, limiting statistical power and precision.
- Single-center design and predominantly male cohort limit generalizability.
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
After a severe heart attack, patients got strong cholesterol drugs. One year later, some stayed in a special lipid clinic, while others went to their regular doctor. Two years later, the special clinic patients had much better cholesterol control.
Research results
In the special clinic group, 72.5 out of 100 reached the cholesterol goal vs 27.5 out of 100 in the GP group. Average LDL cholesterol was 1.2 vs 2.1 mmol/L. Time spent at the cholesterol goal was 82.4% vs 62.4%. Heart events occurred in 7.5% vs 18.8%.
What this means - more context
For every 100 patients, about 45 more reached the cholesterol goal with the special clinic. For heart events, about 8 in 100 in the special clinic had an event vs about 19 in 100 with GP care — an absolute difference of about 11 in 100 — but this difference was not statistically significant, so it could be due to chance. The absolute risk reduction for heart events was not statistically significant in this small study.
To evaluate whether continuing follow-up in a specialized outpatient lipid clinic versus transitioning to general practitioner (GP) care after STEMI affects LDL-C target attainment, time on target, and major adverse cardiac events (MACE) at 24 months in the 'Jena auf Ziel' cohort.
In this prospective single-center cohort of 85 STEMI patients, all received intensive lipid-lowering therapy and reached LDL-C <55 mg/dL by 12 months. From 12 to 24 months, 53 patients stayed in the outpatient lipid clinic and 32 switched to GP care. At 24 months, the lipid clinic group had significantly higher LDL-C target attainment (72.5% vs 27.5%; absolute difference 45 percentage points; p=0.037), lower mean LDL-C (1.2 vs 2.1 mmol/L; p<0.01), and longer time on target (82.4% vs 62.4%; p<0.01). MACE occurred in 7.5% vs 18.8% (absolute difference 11.3 percentage points), but this was not statistically significant. GP deprescribing of lipid-lowering therapy was the main cause of missed targets.
Methods Used
Prospective cohort study of 85 patients admitted with STEMI to Jena University Hospital in 2021. All started atorvastatin 80 mg plus ezetimibe, with escalation to bempedoic acid or PCSK9 inhibitors as needed. At 12 months, patients chose either continued outpatient lipid clinic follow-up (n=53) or GP standard care (n=32). At 24 months, researchers compared prescribed lipid-lowering drugs, LDL-C target attainment, LDL-C time on target, and MACE.
Main Finding
At 24 months, specialized lipid clinic follow-up vs GP care was associated with higher absolute LDL-C target attainment (72.5% vs 27.5%; absolute difference 45 percentage points; p=0.037), lower mean LDL-C (1.2 vs 2.1 mmol/L; p<0.01), and longer time on target (82.4% vs 62.4%; p<0.01). MACE occurred in 7.5% vs 18.8% (absolute difference 11.3 percentage points), but the difference was not statistically significant. Deprescribing by GPs was the main reason for missed LDL-C targets.
Confidence Level
Low to moderate. No retraction or corrections. Small single-center non-randomized cohort (n=85), treatment groups self-selected, no confidence intervals or effect sizes reported, and the MACE analysis was underpowered.
Study Flags
Red Flags
- •Small sample (n=85) and underpowered for MACE
- •Non-randomized treatment selection (patients chose clinic vs GP) and single-center design
- •No confidence intervals or effect sizes reported; retrospective limitation noted
Surprising Findings
Deprescribing of lipid-lowering therapy by GPs was a bigger cause of missed LDL-C targets than patient non-adherence.
Many people assume patients not taking their pills is the main reason cholesterol goals are missed, but this study points to doctors stopping effective medications.
Practical Takeaways
If you or a loved one has had a heart attack, ask about structured lipid clinic follow-up or ensure your GP is committed to aggressive LDL-C targets.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 548 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study watched two groups of heart attack patients: one group got extra care at a special lipid clinic, and the other went to their regular doctor. It can show a link between the type of care and health outcomes, but because patients chose their group and were not randomly assigned, it cannot prove that one type of care caused the difference.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Prospective follow-up of a defined STEMI cohort with complete 24-month follow-up of all 85 patients.
- Objective laboratory measurement of LDL-C and structured assessment of LDL-C target attainment.
- Clinically relevant outcome of MACE, although event numbers were small.
Weaknesses
- Non-randomized allocation: patients chose whether to continue specialized lipid clinic follow-up or transfer to GP care.
- Small sample size and low MACE event count, limiting statistical power and precision.
- Single-center design and predominantly male cohort limit generalizability.
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study followed 85 patients for two years and measured cholesterol and heart problems, which is useful. But it was small, from one hospital, and the two groups might have been different in other ways, so we should be careful trusting the results until bigger randomized studies confirm them.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
40 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=85)+6.9/20
- Follow-up+10/10
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 548 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is a non-randomized, single-center observational cohort study. Patients self-selected to continue in the outpatient lipid clinic or transition to GP care, so groups may differ in unmeasured ways (e.g., health literacy, socioeconomic status, disease severity, adherence). Confounding by indication, selection bias, and small sample size prevent causal inference. Associations between less intensive lipid-lowering therapy, higher LDL-C, and MACE cannot be interpreted as cause-effect relationships.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding sources were disclosed in the manuscript.
The provided text contains no conflict of interest section, no funding statement, and no author affiliations or disclosure statements. The study appears to be an academic, single-center investigation. However, the absence of explicit disclosure prevents full verification of potential conflicts.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Dr Brad Stanfield cite this study, drawing 1 claim from it.
- Good evidence
Good evidence supports this claim, with little to contradict it.
Evidence
Authored by
8 researchersIf this is your work, this is how we attribute it on Fit Body Science. Franz Haertel is listed as the lead author.